A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the ...
Jul 25, 2019
2
1276
Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.
An immunotherapy drug will be made available to some patients with advanced melanoma skin cancer on the NHS in England.
Nov 30, 2018
0
1
Immunotherapy after surgery increased bladder cancer patients' chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at ...
Feb 17, 2023
0
20
For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...
Mar 21, 2022
0
13
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...
Oct 17, 2018
0
123
Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug—a CTLA-4 ...
Apr 8, 2022
0
8
A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden ...
Sep 28, 2019
0
9
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research ...
Aug 8, 2020
0
2
"You see this place on the image? That's where your kidney was," says VCU Massey Cancer Center medical oncologist Asit Paul, M.D., Ph.D., to 69-year-old Thomas Bland. "And the tumors we saw in your lung and other places still ...
Oct 2, 2018
0
12
